Patents by Inventor Scott Gray-Owen
Scott Gray-Owen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11795190Abstract: Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.Type: GrantFiled: December 29, 2018Date of Patent: October 24, 2023Assignees: NATIONAL RESEARCH COUNCIL OF CANADA, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Janelle Sauvageau, Andrew Cox, Xinyi Guo, Scott Gray-Owen
-
Publication number: 20200331949Abstract: Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.Type: ApplicationFiled: December 29, 2018Publication date: October 22, 2020Inventors: Janelle SAUVAGEAU, Andrew COX, Xinyi GUO, Scott GRAY-OWEN
-
Publication number: 20200268774Abstract: Phosphorylated heptose compounds are useful in modulating an immune response in a subject. Also, the compounds are useful as adjuvants.Type: ApplicationFiled: May 11, 2018Publication date: August 27, 2020Applicants: NATIONAL RESEARCH COUNCIL OF CANADA, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Andrew COX, Janelle SAUVAGEAU, Scott GRAY-OWEN, Xinyi GUO
-
Publication number: 20190117756Abstract: The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.Type: ApplicationFiled: October 25, 2018Publication date: April 25, 2019Inventors: Anthony B. Schryvers, Trevor F. Moraes, Scott Gray-Owen
-
Patent number: 10238738Abstract: Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a TIFA activator such heptose-1,7-5 bisphosphate or an analog or derivative thereof. The methods may be used to activate, inhibit or otherwise modify an immune response so as to either prevent or treat infectious or inflammatory diseases or cancer. Also provided are methods to identify compounds capable of modulating immune responses.Type: GrantFiled: October 9, 2015Date of Patent: March 26, 2019Assignee: The Governing Council of the University of TorontoInventors: Scott Gray-Owen, Ryan Gaudet, Rebecca Malott
-
Patent number: 10149900Abstract: The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.Type: GrantFiled: December 1, 2014Date of Patent: December 11, 2018Assignee: Engineered Antigens Inc.Inventors: Anthony B. Schryvers, Trevor F. Moraes, Scott Gray-Owen
-
Publication number: 20170304435Abstract: Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a TIFA activator such heptose-1,7-5 bisphosphate or an analogue or derivative thereof. The methods may be used to activate, inhibit or otherwise modify an immune response so as to either prevent or treat infectious or inflammatory diseases or cancer. Also provided are methods to identify compounds capable of modulating immune responses.Type: ApplicationFiled: October 9, 2015Publication date: October 26, 2017Inventors: Scott Gray-Owen, Ryan Gaudet, Rebecca Malott
-
Publication number: 20160303217Abstract: The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.Type: ApplicationFiled: December 1, 2014Publication date: October 20, 2016Inventors: Anthony B. SCHRYVERS, Trevor F. MORAES, Scott GRAY-OWEN
-
Publication number: 20070154495Abstract: Live vaccines, live-attenuated vaccines, dead vaccines, protein preparations for use in vaccines and OMVs for use in vaccines are free of CEACAM1-binding Opa, though max contain Opa variants that are antigenic but don't bind to CEACAM1.Type: ApplicationFiled: October 8, 2004Publication date: July 5, 2007Applicant: Health Protection AgencyInventors: Andrew Gorringe, Karen Reddin, Scott Gray-Owen, Ian Boulton
-
Patent number: 7118749Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: January 14, 2002Date of Patent: October 10, 2006Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Publication number: 20030088086Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: ApplicationFiled: January 14, 2002Publication date: May 8, 2003Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 6361779Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: May 17, 1996Date of Patent: March 26, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 6358727Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbpl or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: August 5, 1996Date of Patent: March 19, 2002Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 6262016Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: July 21, 1997Date of Patent: July 17, 2001Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 6015688Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: June 7, 1995Date of Patent: January 18, 2000Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 6008326Abstract: Isolated and purified antiserum or antibody specific for an immunogenic material is provided. Such immunogenic material may comprise purified and isolated transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein, recombinant Tbp1 or Tbp2 proteins and isolated and purified Tbp1 and Tbp2 proteins, and synthetic peptides.Type: GrantFiled: June 7, 1995Date of Patent: December 28, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5922323Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: June 7, 1995Date of Patent: July 13, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5922841Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: June 7, 1995Date of Patent: July 13, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5922562Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: November 8, 1994Date of Patent: July 13, 1999Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
-
Patent number: 5708149Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: June 7, 1995Date of Patent: January 13, 1998Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein